Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trial.
- DOI
- 10.1111/dom.14535
- Published
- 2021 Dec
- Container
- Diabetes, obesity & metabolism
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1111/dom.14535,
title = {Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trial.},
author = {Vaduganathan M and Inzucchi SE and Sattar N and Fitchett DH and Ofstad AP and Brueckmann M and George JT and Verma S and Mattheus M and Wanner C and Zinman B and Butler J},
year = {2021},
journal = {Diabetes, obesity \& metabolism},
doi = {10.1111/dom.14535},
url = {https://doi.org/10.1111/dom.14535}
}RIS
TY - JOUR TI - Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trial. AU - Vaduganathan M AU - Inzucchi SE AU - Sattar N AU - Fitchett DH AU - Ofstad AP AU - Brueckmann M AU - George JT AU - Verma S AU - Mattheus M AU - Wanner C AU - Zinman B AU - Butler J PY - 2021 JO - Diabetes, obesity & metabolism DO - 10.1111/dom.14535 UR - https://doi.org/10.1111/dom.14535 ER -
APA
M, V., SE, I., N, S., DH, F., AP, O., M, B., JT, G., S, V., M, M., C, W., B, Z., & J, B. (2021). Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trial.. Diabetes, obesity & metabolism. https://doi.org/10.1111/dom.14535
Source records
- pubmed · retrieved 2026-09-26T23:29:08.394Z